Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab…

Overview of attention for article published in Frontiers in immunology, April 2022

Altmetric Badge

Mentioned by

twitter: 3 X users

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 36,712 followers.

New Research: Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies: Management of… https://t.co/R

19 Apr 2022

Reply Repost Favourite

RT @GarbineLizeaga: Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Th…

19 Apr 2022

Reply Repost Favourite

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies https://t.co/5hZ8ywixaG

19 Apr 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.